The encyclopedia · Strategy & Leadership · Strategic decision · 2021–2024
CanSino bet everything on one COVID vaccine — and lost 94% of its value
CanSino's Convidecia was a COVID blockbuster — RMB 4.3B in 2021. When demand vanished, the company lost RMB 2.8B and 94% of its market cap.
CanSino Biologics · 2023
What happened
CanSino Biologics (康希诺生物) was a Tianjin-based biotech that listed on HKEX in 2019 under the 18A rules. Its lead asset was Convidecia, an adenovirus-vector COVID-19 vaccine approved in China in February 2021. In 2021, revenue exploded to RMB 4.3B and the company posted its first profit, RMB 1.9B. At its peak, CanSino's market cap reached approximately RMB 190B.
The problem was that Convidecia was CanSino's only product. The company invested in 500M doses/year of production capacity, including a Shanghai joint venture valued at RMB 1.019B. In December 2021, Mexico cut its CanSino order by more than half. In 2022, revenue collapsed 76% to RMB 1.035B, with a net loss of RMB 909M. The company's 2022 launch of Convidecia Air, the world's first inhaled COVID vaccine, failed to revive demand.
In 2023, CanSino's revenue fell to just RMB 345M. Net loss widened to RMB 1.483B, driven by RMB 1.8B in asset impairments — the Shanghai JV was written down to RMB 63M from RMB 1.019B and suspended production. The stock fell from a peak of HK$420 to HK$23, a 94% decline. By 2024, revenue recovered slightly to RMB 846M as meningitis vaccines replaced COVID products, but the company was a shadow of its pandemic-era self.
Why it happened
- CanSino staked the entire company on Convidecia, a single product with inherently temporary pandemic demand, and had no diversified pipeline to fall back on
- The company built 500M doses/year of production capacity based on peak demand projections that evaporated within a year
- International expansion (Mexico, partnerships) was based on demand forecasts that collapsed as COVID moved from pandemic to endemic
- The inhaled vaccine (Convidecia Air) launched in 2022 consumed R&D resources but generated negligible revenue
The lesson
Betting your company on a product with temporary demand is not a strategy — it is a countdown. When the pandemic ended, CanSino had nothing else to sell.
Aftermath
CanSino continues to operate as a listed company, but at a fraction of its peak. Its 2024 revenue of RMB 846M came from meningitis vaccines (MCV2, MCV4) approved in 2021-2022 but never scaled during the pandemic. The Shanghai JV was deconsolidated in February 2024. The company's story is a textbook case of single-product dependence in pharma.
Sources
- Futunn — CanSino 2021 annual results: revenue RMB 4.3B, net profit RMB 1.9B
- Google Finance — CanSino stock price (6185.HK), market cap HK$9.55B, 52-week range HK$19.22–HK$56.55
- Reuters — Mexico cuts CanSino vaccine order by more than half (Dec 2021)
spotted an error? The club wants to know.
More like this
Yao Yao Sour Fish — a mainland chain lasted 4 years in Hong Kong, then vanished
UGO U購Select: 100 Hong Kong stores down to 4 as China Resources pulls back
Jumbo Kingdom, Hong Kong's floating restaurant, closed after HK$100M losses and capsized
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.